ClinicalTrials.gg
Not yet recruitingNCT07614087IO TXAUpdated Jun 11, 2026

Plasma Concentrations of Intraosseous Versus Intravenous Tranexamic Acid in Joint Arthroplasty

A Phase 4 interventional study of Tranexamic Acid in Osteoarthritis, sponsored by Hua Luo. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Hua Luo · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing Tranexamic Acid in Osteoarthritis — 3 open to participants now, 3 under way, 1 of them phase 3. Tranexamic Acid · Osteoarthritis.

Planned enrollment
12th of 15
80 · median 149
Started
2026
the only one that year
Phase 4
6 of 15
2 open now
Registered
15th of 15
by date
Lead sponsor
1 of 15
Hua Luo

Among the 15 studies testing Tranexamic Acid in Osteoarthritis, this one is the 12th largest by planned enrollment, is the only one that started in 2026, is one of 6 in phase 4, and was the 15th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

3 of the 15 studies testing Tranexamic Acid in Osteoarthritis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Tranexamic Acid

Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing Tranexamic Acid in Osteoarthritis, or all of them as a file.
02

Study summary

This prospective randomized controlled trial aims to compare the pharmacokinetic profiles of intraosseous and intravenous tranexamic acid administration in patients undergoing primary total joint arthroplasty. Eligible patients undergoing total hip or total knee arthroplasty will be randomly assigned to receive tranexamic acid either through intraosseous injection or intravenous injection at a dose of 15 mg/kg. Blood samples will be collected at predefined time points to evaluate plasma concentrations and pharmacokinetic characteristics of tranexamic acid. Secondary outcomes include coagulation function, intraoperative blood loss, transfusion rate, and hemoglobin changes. The study aims to provide evidence regarding the pharmacokinetic characteristics and clinical feasibility of intraosseous tranexamic acid administration in joint arthroplasty.

Read the detailed description

This study is a prospective randomized controlled trial designed to compare the plasma concentration profiles and pharmacokinetic characteristics of intraosseous and intravenous tranexamic acid administration in patients undergoing primary total joint arthroplasty. Stratified randomization will be used in this study. Participants will first be stratified according to the type of procedure, either total hip arthroplasty (THA) or total knee arthroplasty (TKA). Within each stratum, patients will be randomly assigned in a 1:1 ratio to either the intraosseous administration group or the intravenous administration group using a random number table or a computer generated randomization sequence. This approach ensures a balanced distribution of surgical procedures between the two treatment groups.

A total of 80 patients scheduled for primary total hip arthroplasty or total knee arthroplasty will be enrolled. Sample size calculation was based on an equivalence design with a significance level of 0.05 and a statistical power of 80%. Allowing for an anticipated dropout rate of approximately 10%, 40 patients will be recruited within each surgical stratum (THA and TKA). Within each stratum, participants will be randomly assigned in a 1:1 ratio to either the intraosseous administration group or the intravenous administration group using a computer generated randomization sequence, resulting in 20 patients per treatment group in each stratum.

Eligible participants include patients aged 18 to 80 years with osteoarthritis undergoing primary total hip or total knee arthroplasty and classified as ASA physical status I-III. Key exclusion criteria include coagulation disorders, prior pulmonary embolism, tranexamic acid allergy, severe hepatic or renal dysfunction, anticoagulant use, pregnancy, and body mass index greater than 40 kg/m².

Both groups will receive tranexamic acid at a standardized dose of 15 mg/kg. In the intraosseous group, patients undergoing total knee arthroplasty will receive intraosseous injection into the proximal tibial cancellous bone before tourniquet release, while patients undergoing total hip arthroplasty will receive intraosseous injection into the proximal femoral cancellous bone before skin incision. In the intravenous group, tranexamic acid will be administered intravenously.

Arterial blood samples will be collected at 1 minute, 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 6 hours, and 18 hours after administration for plasma concentration analysis and pharmacokinetic curve construction. Secondary outcomes include coagulation parameters, intraoperative blood loss, transfusion rate, and hemoglobin changes. The study aims to clarify the perioperative pharmacokinetic characteristics and potential clinical value of intraosseous tranexamic acid administration in joint arthroplasty.

03

Conditions studied

  • Osteoarthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 80 years
  • Patients scheduled for primary total hip arthroplasty or total knee arthroplasty
  • Diagnosis of osteoarthritis
  • (ASA) physical status I-III
  • Preoperative ≥ 9 g/dL
  • Ability to provide written
  • Willingness to comply with postoperative follow up and study procedures

Exclusion criteria

Exclusion Criteria:

  • History of coagulation disorders or bleeding disorders
  • History of pulmonary embolism
  • Known allergy to tranexamic acid
  • Pregnancy or breastfeeding
  • Severe hepatic or renal dysfunction
  • Preoperative anticoagulant therapy
  • > 40 kg/m²
  • Body weight \< 45 kg
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Intraosseous TXA Group

    Knee: Before tourniquet release, a dedicated intraosseous needle was inserted into the proximal tibial cancellous bone adjacent to the tibial tubercle, and tranexamic acid (15 mg/kg) was administered intraosseously. Hip: Before skin incision, a dedicated intraosseous needle was inserted into the proximal femoral cancellous bone adjacent to the greater trochanter, and tranexamic acid (15 mg/kg) was administered intraosseously

    Drug: Tranexamic Acid

  • Active comparator
    Intravenous TXA Group

    Participants receive intravenous tranexamic acid administration at a dose of 15 mg/kg during joint arthroplasty.

    Drug: Tranexamic Acid

Interventions

  • Tranexamic acid was administered at a dose of 15 mg/kg during joint arthroplasty. Depending on study group assignment, the drug was administered either through peripheral intravenous injection or intraosseous injection into the proximal tibial or proximal femoral cancellous bone using a dedicated intraosseous needle.

    Also known as: TXA

06

What researchers measure

Primary outcomes

  1. Plasma Concentration of Tranexamic Acid (μg/mL)

    Arterial blood samples will be collected at predefined time points after tranexamic acid administration to evaluate plasma concentrations following intraosseous and intravenous administration.

    Time frame: 1 minute, 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 6 hours, and 18 hours after tranexamic acid administration

Secondary outcomes

  1. D-dimer (mg/L)

    Assessment of perioperative coagulation parameters following intraosseous or intravenous tranexamic acid administration during joint arthroplasty.

    Time frame: Preoperatively and within 18 hours postoperatively

  2. Fibrinogen(g/L)

    Assessment of perioperative coagulation parameters following intraosseous or intravenous tranexamic acid administration during joint arthroplasty.

    Time frame: Preoperatively and within 18 hours postoperatively

  3. Hemoglobin

    Assessment of perioperative hemoglobin changes following intraosseous or intravenous tranexamic acid administration during joint arthroplasty.

    Time frame: Baseline and 18 hours after surgery

07

Study locations

1 site
08

References and documents

Publications

  • Tantavisut S, Artykbay S, Tangwiwat P, Susantitaphong P. Topical tranexamic acid in hip and knee surgery: a meta-analysis of randomized-controlled trials. EFORT Open Rev. 2025 Jul 1;10(7):454-465. doi: 10.1530/EOR-2024-0152. PubMed 40591647 ↗
  • Yoon U, Beausang D, Elia E, Torjman M, Mojica J, Purtill J, Nazarian D, Courtney PM, Kang Y. The effect of tranexamic acid on blood coagulation in primary total hip arthroplasty using rotational thromboelastometry: a randomized controlled trial. EClinicalMedicine. 2025 Jul 21;86:103374. doi: 10.1016/j.eclinm.2025.103374. eCollection 2025 Aug. PubMed 40735345 ↗
  • DeFrancesco CJ, Reichel JF, Gbaje E, Popovic M, Freeman C, Wong M, DeMeo D, Liu J, Gonzalez Della Valle A, Ranawat A, Cross M, Sculco PK, Haskins S, Kim D, Maalouf D, Kirksey M, Jules-Elysee K, Soffin EM, Kumar K, Beathe J, Figgie M, Inglis A Jr, Garvin S, Alexiades M, DelPizzo K, Russell LA, Sideris A, Saleh J, Zhong H, Memtsoudis SG. Effectiveness of oral versus intravenous tranexamic acid in primary total hip and knee arthroplasty: a randomised, non-inferiority trial. Br J Anaesth. 2023 Feb;130(2):234-241. doi: 10.1016/j.bja.2022.11.003. Epub 2022 Dec 14. PubMed 36526484 ↗
  • Mukasa F, Baba T, Hayashi K, Watari T, Ishijima M. Effects of preoperative systemic administration of tranexamic acid alone on postoperative inflammation and pain in total hip arthroplasty: a retrospective cohort study. Arthroplasty. 2025 Jul 4;7(1):35. doi: 10.1186/s42836-025-00320-3. PubMed 40611356 ↗
  • Jovanovic G, Lukic-Sarkanovic M, Lazetic F, Tubic T, Lendak D, Uvelin A. The Effect of Intravenous Tranexamic Acid on Perioperative Blood Loss, Transfusion Requirements, Verticalization, and Ambulation in Total Knee Arthroplasty: A Randomized Double-Blind Study. Medicina (Kaunas). 2024 Jul 21;60(7):1183. doi: 10.3390/medicina60071183. PubMed 39064612 ↗
  • Wilde JM, Copp SN, Ezzet KA, Rosen AS, Walker RH, McCauley JC, Evans AS, Bugbee WD. No Difference in Blood Loss and Risk of Transfusion Between Patients Treated with One or Two Doses of Intravenous Tranexamic Acid After Simultaneous Bilateral TKA. Clin Orthop Relat Res. 2022 Apr 1;480(4):702-711. doi: 10.1097/CORR.0000000000002037. PubMed 35302971 ↗
  • Bakke HK, Fuskevag OM, Nielsen EW, Dietrichs ES. Intramuscular uptake of tranexamic acid during haemorrhagic shock in a swine model. Scand J Trauma Resusc Emerg Med. 2021 Dec 18;29(1):171. doi: 10.1186/s13049-021-00983-2. PubMed 34922577 ↗
  • Bury G, Fitzpatrick C, Heron B, Cullen W, Scully E, Kachurets K, Zacharchenko L. Ukraine Trauma Project: the feasibility of introducing advanced trauma-care skills to frontline emergency medical services responders. BMJ Open. 2023 Nov 9;13(11):e077895. doi: 10.1136/bmjopen-2023-077895. PubMed 37945303 ↗
  • Vallentin MF, Granfeldt A, Meilandt C, Povlsen AL, Sindberg B, Holmberg MJ, Iversen BN, Maerkedahl R, Mortensen LR, Nyboe R, Vandborg MP, Tarpgaard M, Runge C, Christiansen CF, Dissing TH, Terkelsen CJ, Christensen S, Kirkegaard H, Andersen LW. Effect of Intravenous or Intraosseous Calcium vs Saline on Return of Spontaneous Circulation in Adults With Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial. JAMA. 2021 Dec 14;326(22):2268-2276. doi: 10.1001/jama.2021.20929. PubMed 34847226 ↗
  • Armond DN, Goble HM, Hernandez KL, Ewing A, Taraballi F, Park KJ, McCulloch PC. Intraosseous vs. intravenous vancomycin administration in total shoulder arthroplasty: comparable tissue concentrations with better control. J Shoulder Elbow Surg. 2026 Jan;35(1):e22-e29. doi: 10.1016/j.jse.2025.04.027. Epub 2025 Jun 3. PubMed 40472958 ↗
  • Park KJ, Wininger AE, Sullivan TC, Varghese B, Clyburn TA, Incavo SJ. Superior Clinical Results With Intraosseous Vancomycin in Primary Total Knee Arthroplasty. J Arthroplasty. 2025 Oct;40(10):2650-2654. doi: 10.1016/j.arth.2025.04.074. Epub 2025 May 5. PubMed 40334953 ↗
  • Ng JS, van der Werf B, Nicholson L, Farrington W, Young SW. The AAHKS Clinical Research Award: Intraosseous Regional Diclofenac for Postoperative Pain Management in Total Knee Arthroplasty. J Arthroplasty. 2025 Sep;40(S19):S18-S27. doi: 10.1016/j.arth.2025.05.013. Epub 2025 May 9. PubMed 40349862 ↗
  • Brozovich AA, Incavo SJ, Lambert BS, Sullivan TC, Wininger AE, Clyburn TA, Taraballi F, Park KJ. Intraosseous Morphine Decreases Postoperative Pain and Pain Medication Use in Total Knee Arthroplasty: A Double-Blind, Randomized Controlled Trial. J Arthroplasty. 2022 Jun;37(6S):S139-S146. doi: 10.1016/j.arth.2021.10.009. Epub 2022 Mar 7. PubMed 35272897 ↗
  • DeSoucy ES, Davidson AJ, Hoareau GL, Simon MA, Tibbits EM, Ferencz SE, Grayson JK, Galante JM. Pharmacokinetics of Tranexamic Acid via Intravenous, Intraosseous, and Intramuscular Routes in a Porcine (Sus scrofa) Hemorrhagic Shock Model. J Spec Oper Med. 2019 Winter;19(4):80-84. doi: 10.55460/COGQ-2CY1. PubMed 31910476 ↗
  • Newman ZC, Ogbeifun VO, Barbosa CE, McKinley WI, Benjamin AJ, Munar MY, Pramuka PE, McGovern KD, Nordgren RK, Schreiber MA, Rowell SE. Intravenous Versus Intraosseous Use of Tranexamic Acid in Patients With Traumatic Brain Injury. J Surg Res. 2024 Oct;302:798-804. doi: 10.1016/j.jss.2024.08.003. Epub 2024 Sep 2. PubMed 39226704 ↗

Individual participant data

Plan to share: No — IPD will not be shared because no public data sharing plan has been established for this study.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Jun 2026, 0 months later.

Of 54 non-industry phase 4 interventional studies under Osteoarthritis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 60. This study's planned 0 months is below that.

Counting every sponsor, half of 63 studies reached it within 28 months; a quarter within 11 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2026
First posted
May 29, 2026
StartEst.
May 27, 2026
Primary completionEst.
Jun 3, 2026
CompletionEst.
Dec 30, 2026
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07614087
Lead sponsor
Hua Luo
Responsible party
Hua Luo (Doctor, Taizhou Hospital) — Sponsor-investigator
First posted
May 29, 2026
Start date
May 27, 2026 (estimated)
Primary completion
Jun 3, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jun 11, 2026

Study contacts

Hua Luo, Dr.
Contact
luohua66ry@163.com
0576-85190460

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion